LIDEX-E
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LIDEX-E (LIDEX-E).
LIDEX-E (fluocinonide) is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. |
| Excretion | Primarily hepatic metabolism followed by renal excretion of inactive metabolites; less than 5% excreted unchanged in urine; negligible biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is approximately 3.5 hours; clinical context: steady-state achieved rapidly with bid dosing, suitable for short-term use. |
| Protein binding | Greater than 99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Volume of distribution approximately 1.4 L/kg; indicates extensive tissue penetration and distribution into peripheral compartments. |
| Bioavailability | Topical: Bioavailability is variable, estimated at 1-36% depending on skin condition and site; negligible systemic bioavailability from intact skin, increased with damaged skin. |
| Onset of Action | Topical: Onset of vasoconstrictor effect within 1 hour; clinical improvement may be seen within 12-24 hours. |
| Duration of Action | Topical: Duration of vasoconstriction 4-6 hours; clinical duration of anti-inflammatory effect typically 12-24 hours, requiring twice-daily application. |
Apply a thin film to affected area 1-4 times daily; topical; do not use occlusive dressings.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required; topical administration with negligible systemic absorption. |
| Liver impairment | No dose adjustment required; topical administration with negligible systemic absorption. |
| Pediatric use | Apply a thin film to affected area 1-2 times daily; avoid prolonged use and occlusive dressings. Limit quantity to lowest effective dose due to increased systemic absorption risk. |
| Geriatric use | Use with caution; apply sparingly to affected area 1-2 times daily. Avoid prolonged use and occlusive dressings due to increased skin atrophy risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LIDEX-E (LIDEX-E).
| Breastfeeding | It is unknown whether topical fluocinonide is excreted in human breast milk after topical application. However, systemic absorption after topical use is minimal, and it is unlikely to result in detectable levels in breast milk. Use caution when applying to large areas, damaged skin, or under occlusive dressings. The M/P ratio has not been determined. When possible, apply to the smallest area and avoid the breast area to minimize infant exposure. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used appropriately during pregnancy. However, high potency corticosteroids, such as fluocinonide (the active ingredient in LIDEX-E), should be used with caution, especially in the first trimester. Prolonged or extensive use may increase the risk of fetal growth restriction and adrenal suppression. No specific teratogenic effects have been consistently reported in humans, but animal studies have shown an increased risk of cleft palate and other malformations with systemic exposure. Therefore, use the lowest effective potency, minimal quantity, and shortest duration possible. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to fluocinonide or any component of the formulation","Viral, fungal, or tuberculous skin infections","Ophthalmic use"]
| Precautions | ["Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, and hyperglycemia","Prolonged use, use on large areas, occlusive dressings, or in pediatric patients increases risk","Avoid use on face, axillae, or groin without medical supervision"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal adrenal function if used long-term or over large body surface areas. Fetal growth and well-being should be assessed with serial ultrasound if used extensively or for prolonged periods. No specific fetal monitoring is required for short-term, limited use. |
| Fertility Effects | No specific studies on the effect of topical fluocinonide on fertility have been conducted. However, systemic corticosteroids can affect hormonal balance and menstrual cycles. Based on the low systemic absorption of topical application, it is unlikely to significantly impact fertility. |